Accueil・Liste d'Actions・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Fermé

SecteurSoins de santé

4.13 -3.5

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.12

Max

4.28

Chiffres clés
By Trading Economics
Revenu	11M 51M
Ventes	6.5M 113M
P/E Moyenne du Secteur	5.45 57.371
BPA	0.31
Marge bénéficiaire	45.374
Employés	100
EBITDA	6.2M 81M

Dividendes
By Acuity
Prochains Résultats	9 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-7.1M 720M
Ouverture précédente	7.63
Clôture précédente	4.13

Sentiment de l'Actualité

By Acuity

32%

68%

104 / 340 Classement par Healthcare

Ironwood Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 août 2026, 21:51 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

20 août 2026, 20:06 UTC

Ironwood Pharmaceuticals Inc shares are lower during Thursday's session, reversing earlier gains amid rising crude oil prices and increasing U.S. Treasury yields.

19 août 2026, 19:46 UTC

Ironwood Pharmaceuticals shares are higher, supported by declining bond yields and broader market trends. The stock is trading near the upper end of its one-month range.

18 août 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today amid cautious market sentiment influenced by rising treasury yields and inflation concerns.

17 août 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, maintaining its position near the upper end of its one-month range amid rising Treasury yields and inflation concerns.

14 août 2026, 23:01 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, following a drop in U.S. retail sales that raised concerns about consumer spending and economic health.

13 août 2026, 23:36 UTC

Ironwood Pharmaceuticals Inc shares are lower during after-market hours, with no specific news identified to explain the decline. Trading activity remains routine.

12 août 2026, 19:21 UTC

Ironwood Pharmaceuticals is higher Wednesday, buoyed by overall strength in U.S. stocks, despite a recent pullback earlier in the session.

11 août 2026, 22:06 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

10 août 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today, with no specific news identified. The stock remains significantly down since Friday's close amid broader market volatility.

7 août 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc shares are higher during Friday's session, maintaining a position above the 20-day moving average, despite earlier fluctuations.

6 août 2026, 23:06 UTC

Ironwood Pharmaceuticals shares are higher in after-market hours, reflecting positive movement since Thursday's close. No specific news was identified to explain the price action.

5 août 2026, 23:02 UTC

Ironwood Pharmaceuticals shares are higher in after-market trading, continuing a notable increase since Wednesday's close, despite no specific news identified.

4 août 2026, 23:01 UTC

Ironwood Pharmaceuticals Inc. shares are lower in after-market trading, showing routine volatility while remaining above the 20-day moving average. No specific news was identified.

3 août 2026, 19:26 UTC

Ironwood Pharmaceuticals is trading higher today, continuing a rally since Friday's close, amid broader market gains and falling energy prices.

31 juil. 2026, 23:26 UTC

Ironwood Pharmaceuticals Inc shares are trading higher in after-market hours, maintaining upward momentum since Friday's close. No specific news was identified for this movement.

30 juil. 2026, 20:51 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, despite broader market gains. The stock remains below its 20-day moving average and near a one-month low.

29 juil. 2026, 20:04 UTC

Ironwood Pharmaceuticals Inc shares are trading lower amid broader market dynamics, including rising oil prices due to escalating Middle East tensions.

27 juil. 2026, 20:06 UTC

Ironwood Pharmaceuticals shares are higher today, reflecting broader market dynamics, despite earlier declines and a significant drop in oil prices.

24 juil. 2026, 23:26 UTC

Ironwood Pharmaceuticals shares gained modestly in after-market trading, following a volatile session amid broader turmoil in the bond market.

20 juil. 2026, 18:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, reaching a session peak before settling within its one-month range. No specific news was identified for today's movement.

Comparaison

Variation de prix

Ironwood Pharmaceuticals Inc prévision

Note du Consensus

By TipRanks

Achat

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

104 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.